美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Invesco Nasdaq Biotechnology ETF

34.36

+0.10590.31%

盤後：34.35-0.0059-0.02%19:59 EDT

成交量：1.97萬

成交額：67.75萬

市值：9,550.94萬

市盈率：- -

高：34.62

開：34.39

低：34.20

收：34.25

52周最高：36.84

52周最低：23.42

股本：278.00萬

流通股本：278.00萬

量比：0.95

換手率：0.71%

股息：0.26

股息率：0.75%

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

AI 製藥迎來價值兑現期，創新藥產業打開全新增長空間

独角兽智库

PHARVARIS的3期臨床試驗達到全部主要及次要終點。

石藥集團：SYH2083滴眼液獲臨床試驗批准

膽固醇藥物臨床試驗受挫，數十億美元研發競賽蒙上陰影

环球市场播报

諾華試驗受挫且BMO下調評級，安進股價下跌

復星醫藥(600196.SH)子公司FXS5626片獲臨床試驗批准

盤前異動：安進、耐克、Bloom Energy 等個股受關注

美股異動｜安進盤前跌5.4%，諾華同靶點藥物III期臨床失敗，Lp(a)賽道遭重創

製藥巨頭諾華股價大跌近10%，遭遇三項藥物臨床試驗受挫

环球市场播报

安進股價盤前下跌5.4%；競爭對手諾華的膽固醇藥物後期臨床試驗失敗。

邁普醫學(301033.SZ)：「可吸收止血流體明膠」進入臨床試驗階段

邁普醫學：可吸收止血流體明膠作為第三類醫療器械進入臨床試驗

創新藥概念午後拉升，亞太藥業直線漲停，百普塞斯升逾10%，萬邦醫藥、皓元醫藥升逾6%。

諾華DM1藥物III期臨床試驗未達到主要終點

酶的戰爭：一場或將重塑全球創新藥競爭格局的「皮下革命」

富國銀行上調安進目標價至435美元

上半年創新藥冰火兩重天：百濟神州一款藥賣了超160億元，六成藥企還在求生

每日经济新闻

石藥集團(01093)：SYH2085片用於治療成人單純性流感的II期臨床試驗在中國正式啓動

石藥集團：SYH2085片II期臨床試驗在中國正式啓動

繼諾華之後，諾和諾德(NVO.US)終止兩項心血管臨床試驗

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/hant/stock/IBBQ/news?page=8"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"IBBQ","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBBQ\",,,,,undefined,":{"symbol":"IBBQ","market":"US","secType":"STK","nameCN":"Invesco Nasdaq Biotechnology ETF","latestPrice":34.3559,"timestamp":1789588800000,"preClose":34.25,"halted":0,"volume":19691,"hourTrading":{"tag":"盘后","latestPrice":34.35,"preClose":34.3559,"latestTime":"19:59 EDT","volume":40,"amount":1379.2795,"timestamp":1789603165220,"change":-0.0059,"changeRate":-0.000172,"amplitude":0},"delay":0,"changeRate":0.003091970802919659,"floatShares":2780001,"shares":2780001,"eps":0,"marketStatus":"已收盤","change":0.1059,"latestTime":"09-16 16:00:00 EDT","open":34.39,"high":34.62,"low":34.1992,"amount":677542.144902,"amplitude":0.012286,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1789632000000},"marketStatusCode":5,"adr":0,"exchange":"NASDAQ","adjPreClose":34.25,"sharesOutstanding":2520001,"nav":34.27126,"aum":95274137.07126,"dividendRate":0.007478,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":34.28,"preClose":34.25,"latestTime":"09:29 EDT","volume":69,"amount":2360.8497660000003,"timestamp":1789565397037,"change":0.03,"changeRate":0.000876,"amplitude":0.008175},"postHourTrading":{"tag":"盘后","latestPrice":34.35,"preClose":34.3559,"latestTime":"19:59 EDT","volume":40,"amount":1379.2795,"timestamp":1789603165220,"change":-0.0059,"changeRate":-0.000172,"amplitude":0},"volumeRatio":0.950696,"impliedVol":0.1125,"impliedVolPercentile":0.4741},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBBQ\",,,,,undefined,":{"symbol":"IBBQ","floatShares":2780001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.950696,"shares":2780001,"dividePrice":0.2569,"high":34.62,"amplitude":0.012286,"preClose":34.25,"low":34.1992,"week52Low":23.42,"pbRate":"--","week52High":36.84,"institutionHeld":0,"latestPrice":34.3559,"eps":0,"divideRate":0.007478,"volume":19691,"delay":0,"ttmEps":0,"open":34.39,"prevYearClose":28.3962,"prevWeekClose":34.472,"prevMonthClose":35.4742,"prevQuarterClose":32.66,"fiveDayClose":34.9277,"twentyDayClose":34.6197,"sixtyDayClose":30.4995},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IBBQ\",params:#limit:5,,,undefined,":[{"date":"2026-06-22","symbol":"IBBQ","amount":0.03422,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-22","defaultRemindTime":1782135000000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-26","payableDate":"2026-06-22","currency":"USD","dateTimestamp":1782100800000,"payDate":"2026-06-26"},{"date":"2026-03-23","symbol":"IBBQ","amount":0.03609,"announcedDate":"2026-03-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-23","defaultRemindTime":1774272600000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-27","payableDate":"2026-03-23","currency":"USD","dateTimestamp":1774238400000,"payDate":"2026-03-27"},{"date":"2025-12-22","symbol":"IBBQ","amount":0.0906,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-26","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-26"},{"date":"2025-09-22","symbol":"IBBQ","amount":0.09576,"announcedDate":"2025-09-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-22","defaultRemindTime":1758547800000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-26","payableDate":"2025-09-22","currency":"USD","dateTimestamp":1758513600000,"payDate":"2025-09-26"},{"date":"2025-06-23","symbol":"IBBQ","amount":0.0287,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-23","defaultRemindTime":1750685400000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-27","payableDate":"2025-06-23","currency":"USD","dateTimestamp":1750651200000,"payDate":"2025-06-27"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IBBQ\",market:\"US\",,,undefined,":[{"executeDate":"2021-09-20","recordDate":"2021-09-21","paymentDate":"2021-09-30","value":0.04324,"currency":"USD"},{"executeDate":"2021-12-20","recordDate":"2021-12-21","paymentDate":"2021-12-31","value":0.10511,"currency":"USD"},{"executeDate":"2022-03-21","recordDate":"2022-03-22","paymentDate":"2022-03-31","value":0.03778,"currency":"USD"},{"executeDate":"2022-06-21","recordDate":"2022-06-22","paymentDate":"2022-06-30","value":0.04264,"currency":"USD"},{"executeDate":"2022-09-19","recordDate":"2022-09-20","paymentDate":"2022-09-23","value":0.03769,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IBBQ\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IBBQ\",pageSize:20,pageCount:8,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2665320908","title":"AI 製藥迎來價值兑現期，創新藥產業打開全新增長空間","url":"https://stock-news.laohu8.com/highlight/detail?id=2665320908","media":"独角兽智库","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665320908?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 19:44","pubTimestamp":1788867840,"startTime":"0","endTime":"0","summary":"AI 制药行业已经走过早期概念炒作阶段，产业验证层级持续向上，从算法叙事正式转向管线价值兑现，行业商业化拐点正在加速到来。随着 AI 制药行业持续发展，生物测序数据需求持续扩张，设备与试剂业务打开增量空间，站在产业链上游充分受益行业整体景气上行。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-09-08/doc-inircmes6042281.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159992","BK1191","01477","MEDX","BK1161","LNGR","CHAT","IBBQ","06978","BK1574","AIPO","QTOC","AGIX","ARTY","VTHR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665324003","title":"PHARVARIS的3期臨床試驗達到全部主要及次要終點。","url":"https://stock-news.laohu8.com/highlight/detail?id=2665324003","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665324003?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 18:53","pubTimestamp":1788864791,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MDTX","BMED","IBBJ","PSYK","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665329150","title":"石藥集團：SYH2083滴眼液獲臨床試驗批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2665329150","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665329150?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 17:51","pubTimestamp":1788861091,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MDTX","PSYK","IBBQ","BMED","IBBJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665329827","title":"膽固醇藥物臨床試驗受挫，數十億美元研發競賽蒙上陰影","url":"https://stock-news.laohu8.com/highlight/detail?id=2665329827","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665329827?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 17:33","pubTimestamp":1788859980,"startTime":"0","endTime":"0","summary":"受该消息影响，诺华周一股价下跌 3%。诺华表示完整试验结果将在后续医学学术大会上公布。诺华强调，本次 8000 多名受试者均已接受最优标准治疗。诺华失利，安进与礼来压力陡增此前分析师测算，如果 pelacarsen 临床试验成功，其销售峰值有望达到每年 4050 亿美元。但该临床试验的冲击不止波及诺华一家。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-09-08/doc-inirceww4625928.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["MDTX","BMED","IBBJ","PSYK","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665215326","title":"諾華試驗受挫且BMO下調評級，安進股價下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2665215326","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665215326?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 17:27","pubTimestamp":1788859661,"startTime":"0","endTime":"0","summary":"BUZZ-诺华试验受挫且BMO下调评级，安进股价下跌9月8日-** 安进公司（AMGN.O）股价盘前下跌4.8%，至416美元** 诺华公司（NOVN.S）的降胆固醇药物在一项备受关注的研究中未能达标，这引发了市场对安进公司（Amgen）实验性降胆固醇药物olpasiran的担忧 (link)** 摩根大通分析师表示，诺华的pelacarsen研究结果降低了市场对安进olpasiran的预期，而该","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nL4T4500MM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4534","BK4139","IE00B4R5TH58.HKD","BK4599","LU1057294990.SGD","LU0058720904.USD","LU1023059063.AUD","LU0889565916.HKD","TBXU","AMGN","IE00B2B36J28.USD","LU2468319806.SGD","BK4585","PJP","SG9999001440.SGD","LU1983299246.USD","LU1571399168.USD","IE00BFTCPJ56.SGD","LU0109394709.USD","LU0868494617.USD","LU0320765992.SGD","PBE","BK4588","BIB","LU1061106388.HKD","IBBQ","BBH","LU0122379950.USD","IE0009355771.USD","IE00BJT1NW94.SGD","BK4566","LU2242652126.USD","IBB","IE00BJJMRZ35.SGD","BK4533","BK4581","LU2242646821.SGD","LU2112291526.USD","LU2089984988.USD","LU0289739699.SGD","IE0002141913.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665132698","title":"復星醫藥(600196.SH)子公司FXS5626片獲臨床試驗批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2665132698","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665132698?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 17:13","pubTimestamp":1788858794,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药 发布公告，近日，公司控股子公司上海复星医药产业发展有限公司收到国家药品监督管理局关于同意FXS5626片用于治疗非节段型白癜风开展II/III期适应性无缝设计临床试验的批准。复星医药产业拟于条件具备后于中国境内开展该药品的相关临床研究。截至2026年8月，公司现阶段针对FXS5626的累计研发投入约为1.08亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493360.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0187","BK1593","BK0012","BK0188","02196","BK1191","IBBJ","PSYK","600196","BK0096","BK0175","BK0028","BK0060","MDTX","BK0183","BK0239","BMED","BK0196","IBBQ","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176595225","title":"盤前異動：安進、耐克、Bloom Energy 等個股受關注","url":"https://stock-news.laohu8.com/highlight/detail?id=1176595225","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176595225?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 17:10","pubTimestamp":1788858632,"startTime":"0","endTime":"0","summary":"安进：这家生物科技巨头、道琼斯指数的重要权重股，其盘前股价重挫逾5%。此前，瑞士制药商诺华宣称，其一款实验性药物在晚期临床试验中未能有效降低心血管风险。安进与礼来目前正在各自研发竞品疗法以应对挑战。消息传出后，诺华在欧股市场大跌10%，礼来股价亦小幅走低。Bloom Energy：这家燃料电池制造商可谓利好连连。受此提振，其盘前股价上扬4%。游戏驿站定于今日美股收盘后发布财报。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07399","IE00BJT1NW94.SGD","MSTW","LU2098885051.SGD","CRPT","HOOX","BK4599","BK4532","PJP","BPAY","MSST","NVS","CONL","SMST","LU0823414478.USD","HOOZ","COII","ROBN","07799","FIAT","IE00BJJMRZ35.SGD","LU0708994859.HKD","LU2360107671.USD","LU0122379950.USD","MSTK","BBH","LU0058720904.USD","IMST","OWNB","LMI3.UK","BK4561","COIO","BK4533","EGGY","BK4596","LU1057294990.SGD","LU1303367103.USD","LU1861559042.SGD","BK4182","CONY","GMEC","CONX","HODU","LU1267930813.SGD","LU0957808578.USD","BK4127","FDIG","IBLC","07311","MSTZ","LU2249611893.SGD","LU1988902786.USD","LU0070302665.USD","09711","LU2089984988.USD","LU0052756011.USD","APED","BK4541","BK4539","BK4581","LU1861220207.SGD","BK4516","VTWG","MSTR","BK4600","LU0211331839.USD","ICLN","GMEY","IE0009355771.USD","LU0889566641.SGD","BK4146","COIG","CONI","LU0109394709.USD","LU0823414551.USD","LU0868494617.USD","LU2468319806.SGD","IGME","LU0476273544.USD","LU0208291251.USD","NKE","PPH","COYY","09399","LU0128525689.USD","LU0128525929.USD","3SMI.UK","BE","BK4566","LU0289739699.SGD","TBXU","BK4007","SIMS","04332","ICOI","LU1064131342.USD","UPGR","LU2264538146.SGD","LU1642822529.SGD","LU1267930227.SGD","HOOD","MSOO","BK4139","MSTY.UK","BK4558","BK4578","HOOI","BEZ","LU2357125470.USD","MSTP","ZAP","LU0029864427.USD","COIA","IE00BFTCPJ56.SGD","LU2506951792.HKD","SMI3.UK","MSTX","HOYY","LU2543165471.USD","LU1571399168.USD","BITQ","GME","MSDD","IE0009354923.USD","BK4588","HOOW","LU0310800379.SGD","IE00B2B36J28.USD","AMGN","IE0002141913.USD","HOOG","MTYY","BK4585","BK4112","BEX","IE00BFXG0V08.USD","MST","FINX","BLCK","IE00B4R5TH58.HKD","LU1267930573.SGD","LU0823411888.USD","DAPP","LU0889565916.HKD","LU1861558580.USD","BEG","07711","WNTR","BK4554","IE00BYQQ9H92.USD","09799","BK4534","COIN","BK4577","LU0444973449.USD","HOOY","MEDX","MSTU","COIX","CTEC","HOOC","IAI","BK4023","LU2112291526.USD","VCLN","BK4595","LU0320765992.SGD","BKCH","LU0320765489.SGD","LU1815336760.USD","LU1983299246.USD","BK4547","BK4076","LU1061106388.HKD","09311","BK4535","HOII","LU0786609619.USD","BEC","IBBQ","STYL","LU0792757196.USD","SG9999001440.SGD","COIW","IBAT","PBE","LU2294711713.HKD","GMEU","FRNW","LU1861217088.USD","BK4551","3LMI.UK","LU0310800965.SGD","MSTC","WATS","MSTY","CNRG","LU0444971666.USD","SMOG","MSII","LU2242646821.SGD","IBB","BIB","LU1023059063.AUD","LU2242652126.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665326953","title":"美股異動｜安進盤前跌5.4%，諾華同靶點藥物III期臨床失敗，Lp(a)賽道遭重創","url":"https://stock-news.laohu8.com/highlight/detail?id=2665326953","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665326953?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 17:07","pubTimestamp":1788858422,"startTime":"0","endTime":"0","summary":"消息面上，诺华于9月4日公布，其与Ionis联合开发的降脂药物Pelacarsen，在名为LpHORIZON的III期临床试验中未能达到主要终点。诺华的Pelacarsen是全球首个针对Lp靶点进行心血管结局验证的III期药物。因此，市场担忧情绪蔓延到了同样在开发Lp药物的安进身上。多家分析机构认为，诺华的失败削弱了但并未完全推翻Lp这一靶点的可行性。安进后续公布的Olpasiran完整试验数据，将成为判断该靶点未来走向的关键。","market":"us","thumbnail":" http://caiji.3g.cnfol.com/colect/202609/08/20260908512020.jpg","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202609/08/20260908512020.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260908/32363493.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK4532","BK4533","IE00B2B36J28.USD","LU0109394709.USD","LU0058720904.USD","BK4588","LU0868494617.USD","IE00B4R5TH58.HKD","TBXU","LU0211331839.USD","BK4581","LU0122379950.USD","IBB","IE0002141913.USD","PPH","IE0009355771.USD","NVS","PBE","LU2242652126.USD","IE00BJT1NW94.SGD","LU0320765489.SGD","LU0320765992.SGD","BK4578","BK4599","LU0289739699.SGD","SG9999001440.SGD","IE00BJJMRZ35.SGD","LU2468319806.SGD","BK4007","LU0070302665.USD","IE00BFTCPJ56.SGD","AMGN","LU0889565916.HKD","LU2112291526.USD","BBH","LU0208291251.USD","LU1983299246.USD","PJP","BK4534","IBBQ","LU1023059063.AUD","BK4139","BK4566","LU2089984988.USD","MEDX","BIB","LU1061106388.HKD","LU1057294990.SGD","BK4585","LU1571399168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665257563","title":"製藥巨頭諾華股價大跌近10%，遭遇三項藥物臨床試驗受挫","url":"https://stock-news.laohu8.com/highlight/detail?id=2665257563","media":"环球市场播报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665257563?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 16:50","pubTimestamp":1788857448,"startTime":"0","endTime":"0","summary":"该股最新跌幅达 9.4%。一周之内接连遭遇第三起临床试验挫折，引发投资者抛售，股价或将创下上市以来最差单日交易记录。德尔德西兰临床试验失利数日之前，诺华另一款用于降低心血管事件风险的药物刚在晚期临床试验遇挫；一周前，诺华还宣布，因三名受试者死亡，暂停了实验性细胞疗法 rapcel 的八项临床试验。","market":"us","thumbnail":"http://n.sinaimg.cn/finance/transform/59/w550h309/20260908/d06c-43061a4fc4516fcb77a4d9ff51620de1.png","type":0,"news_type":0,"thumbnails":["http://n.sinaimg.cn/finance/transform/59/w550h309/20260908/d06c-43061a4fc4516fcb77a4d9ff51620de1.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-09-08/doc-inirceww4608579.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina_us","symbols":["BK4588","LU0070302665.USD","BK4007","BMED","LU0320765489.SGD","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","BK4578","IBBQ","BK4532","PSYK","IBBJ","IE00BFTCPJ56.SGD","IE00B4R5TH58.HKD","IE00BJT1NW94.SGD","LU0208291251.USD","LU0211331839.USD","MEDX","NVS","IE0002141913.USD","MDTX","IE0009355771.USD","PPH","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665258833","title":"安進股價盤前下跌5.4%；競爭對手諾華的膽固醇藥物後期臨床試驗失敗。","url":"https://stock-news.laohu8.com/highlight/detail?id=2665258833","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665258833?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 16:28","pubTimestamp":1788856084,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE00BFTCPJ56.SGD","MDTX","PPH","LU0889565916.HKD","BBH","BK4534","LU0122379950.USD","BIB","LU0211331839.USD","BK4007","IBBJ","LU2089984988.USD","SG9999001440.SGD","BK4585","BK4533","BK4578","IBBQ","LU1023059063.AUD","LU2468319806.SGD","IE00BJT1NW94.SGD","NVS","BMED","IE0002141913.USD","LU0320765489.SGD","LU0109394709.USD","LU2242646821.SGD","LU0070302665.USD","LU1061106388.HKD","IBB","LU0320765992.SGD","BK4532","BK4566","LU2242652126.USD","TBXU","LU2112291526.USD","LU1057294990.SGD","AMGN","LU0058720904.USD","PSYK","MEDX","BK4599","IE00BJJMRZ35.SGD","LU0289739699.SGD","PJP","BK4581","LU0868494617.USD","LU1983299246.USD","PBE","LU0208291251.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665323037","title":"邁普醫學(301033.SZ)：「可吸收止血流體明膠」進入臨床試驗階段","url":"https://stock-news.laohu8.com/highlight/detail?id=2665323037","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665323037?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 16:21","pubTimestamp":1788855709,"startTime":"0","endTime":"0","summary":"智通财经APP讯，迈普医学(301033.SZ)发布公告，公司的研发项目“可吸收止血流体明胶”于近期正式进入临床试验阶段。该医疗器械临床用途：在外科手术中，当压迫、结扎、电凝或其他传统的止血方法无法控制小动脉、静脉及毛细血管的出血，或上述方法无法操作时，可使用可吸收止血流体明胶进行辅助止血。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493299.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["PSYK","301033","IBBJ","BMED","BK0251","IBBQ","MDTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665332349","title":"邁普醫學：可吸收止血流體明膠作為第三類醫療器械進入臨床試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2665332349","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665332349?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 16:14","pubTimestamp":1788855283,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BMED","IEIH","PTH","GDOC","HART","IBBQ","LGHT","MDTX","MDEV","MEDX","PSYK","AGNG","RSPH","IBBJ","LNGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665342986","title":"創新藥概念午後拉升，亞太藥業直線漲停，百普塞斯升逾10%，萬邦醫藥、皓元醫藥升逾6%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2665342986","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665342986?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 13:44","pubTimestamp":1788846270,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBQ","MEDX","LNGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665342373","title":"諾華DM1藥物III期臨床試驗未達到主要終點","url":"https://stock-news.laohu8.com/highlight/detail?id=2665342373","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665342373?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 13:31","pubTimestamp":1788845477,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["MDTX","IBBQ","LU0208291251.USD","BK4532","IE0009355771.USD","LU0320765489.SGD","BMED","IE00B4R5TH58.HKD","IE00BJT1NW94.SGD","LU0211331839.USD","IE00BFTCPJ56.SGD","IE00B2B36J28.USD","PSYK","BK4578","IBBJ","NVS","BK4585","BK4588","IE00BJJMRZ35.SGD","BK4007","LU0070302665.USD","PPH","IE0002141913.USD","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665341826","title":"酶的戰爭：一場或將重塑全球創新藥競爭格局的「皮下革命」","url":"https://stock-news.laohu8.com/highlight/detail?id=2665341826","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665341826?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 11:13","pubTimestamp":1788837196,"startTime":"0","endTime":"0","summary":"算上诺华，已有10家全球制药巨头为ALT-B4签下许可协议。有意思的地方在于：这些交易里没有一款新药。2025年9月，默沙东的Keytruda Qlex获FDA批准，成为首个使用ALT-B4的商业化产品。第一张牌，宝济药业的“国产first”。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1788753577275365008","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["06978","159992","MEDX","IBBQ","BK1161","LNGR","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665349003","title":"富國銀行上調安進目標價至435美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2665349003","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665349003?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 11:12","pubTimestamp":1788837128,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU1023059063.AUD","BK4599","LU2242652126.USD","BK4582","IBB","AMGN","UUP","BK4533","LU2112291526.USD","LU2089984988.USD","TBXU","LU0058720904.USD","LU0320765992.SGD","BK4534","BK4581","IE00BJJMRZ35.SGD","BK4139","LU0289739699.SGD","PGF","IE0009355771.USD","IE00B4R5TH58.HKD","IBBQ","PBE","LU2242646821.SGD","IE0002141913.USD","LU1571399168.USD","BIB","LU2468319806.SGD","BK4588","IE00BJT1NW94.SGD","SG9999001440.SGD","IE00BFTCPJ56.SGD","LU1057294990.SGD","LU0889565916.HKD","BK4585","LU0109394709.USD","LU1061106388.HKD","PJP","IE00B2B36J28.USD","UDN","BK4566","BBH","LU0122379950.USD","LU0868494617.USD","LU1983299246.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665311078","title":"上半年創新藥冰火兩重天：百濟神州一款藥賣了超160億元，六成藥企還在求生","url":"https://stock-news.laohu8.com/highlight/detail?id=2665311078","media":"每日经济新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665311078?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 20:39","pubTimestamp":1788784781,"startTime":"0","endTime":"0","summary":"2026年上半年财报季收官，中国创新药产业交出了一份分水岭式的答卷。行业正在告别“烧钱讲故事”的阶段，走向“赚钱才是硬道理”的价值兑现期。这种转变并非行业普遍现象，而是由商业化放量、出海授权爆发、资金来源多元化三重力量共同推动的分化。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609073866904351.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609073866904351.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1500","KURE","BK1588","BK4139","ONC","688235","MEDX","LU1303224171.USD","LU1969619763.USD","LU1719994722.HKD","LU0828237510.HKD","BK4526","BK1583","LU0588546209.SGD","159992","LU0307460666.USD","BK1161","LU1770034418.SGD","BK4588","LU1251922891.USD","BK0239","IBBQ","BK1574","BK4585","06160","LNGR","LU0228659784.USD","LU2328871848.SGD","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665319978","title":"石藥集團(01093)：SYH2085片用於治療成人單純性流感的II期臨床試驗在中國正式啓動","url":"https://stock-news.laohu8.com/highlight/detail?id=2665319978","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665319978?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 19:30","pubTimestamp":1788780616,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药集团 发布公告，集团开发的SYH2085片用于治疗成人无并发症的单纯性流行性感冒的II期临床试验已于中国首家中心正式启动。此前，集团已于2025年12月获中国国家药品监督管理局就该产品签发的《药物临床试验批准通知书》。本次启动的该产品临床试验为多中心、随机、双盲、安慰剂对照的II期临床研究，旨在评价该产品治疗中国成人无并发症的单纯性流行性感冒参与者中的有效性及安全性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1492970.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00BZ08YT58.USD","BK1191","LU1951186391.HKD","LU1807302812.USD","IE0008368742.USD","LU0326950275.SGD","LU1226287792.SGD","LU1226288253.USD","IE00B543WZ88.USD","IBBQ","IE00BZ08YR35.GBP","BMED","LU0072913022.USD","LU0501845795.SGD","LU1226288170.HKD","LU1008478684.HKD","PSYK","LU2039709279.SGD","MDTX","LU1226287875.USD","IBBJ","IE00B031HY20.USD","BK1521","LU0315179316.USD","01093","LU1226287529.USD","LU1328277881.USD","KURE","LU0067412154.USD","LU0140636845.USD","LU1152091168.USD","IE00B5MMRT66.SGD","SG9999004220.SGD","IE0008369823.USD","LU0314109678.HKD","LU1993786604.SGD","HK0000165453.HKD","LU1152091754.HKD","LU0880133367.SGD","BK1515","LU1960683339.HKD","LU1813983027.USD","IE00BZ08YS42.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665319936","title":"石藥集團：SYH2085片II期臨床試驗在中國正式啓動","url":"https://stock-news.laohu8.com/highlight/detail?id=2665319936","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665319936?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 19:28","pubTimestamp":1788780492,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["PSYK","MDTX","BMED","IBBQ","IBBJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665831989","title":"繼諾華之後，諾和諾德(NVO.US)終止兩項心血管臨床試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2665831989","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665831989?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 19:10","pubTimestamp":1788779458,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["PPH","IE0009355771.USD","IE00B4R5TH58.HKD","BMED","BK4532","IE00BJJMRZ35.SGD","NVS","LU0211331839.USD","MEDX","IE0002141913.USD","BGIA","IE00BJT1NW94.SGD","IBBJ","BK4578","PSYK","BK4588","LU0320765489.SGD","MDTX","BK4007","LU0070302665.USD","IE00BFTCPJ56.SGD","IE00B2B36J28.USD","BK4585","IBBQ","LU0208291251.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":11,"pageCount":8,"totalSize":218,"code":"91000000","status":"200"}]}}